Product Description
An ultrasound is an imaging test that uses sound waves to create a picture (also known as a sonogram) of organs, tissues, and other structures inside the body. Unlike x-rays, ultrasounds don't use any radiation.
Mechanisms of Action: Imaging Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Australia | Colombia | India | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang University
Company Location: Asia Pacific
Company Founding Year: 1897
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Netherlands, Sweden, United States
Active Clinical Trial Count: 22
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Osteoarthritis, Knee|Prostate Cancer
Phase 2: Arthritis, Rheumatoid|Colorectal Cancer|Edema|GM1 Gangliosidosis|Gangliosidoses|Gangliosidosis, GM1|Neuromyelitis Optica
Phase 1: Acute Kidney Injury|Adenocarcinoma|Glioblastoma|Glioma|Hip Dislocation, Congenital|Hyperlipidemia|Hypertension, Renal|Kidney Failure, Chronic|Obesity|Osteoarthritis|Other|Overweight|Pain Unspecified|Pancreatic Cancer|Peripheral Arterial Disease|Peripheral Vascular Diseases|Prediabetes|Prediabetic State|Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07165340 |
HSC-MS-25-0191 | P2 |
Enrolling by invitation |
Edema|Neuromyelitis Optica |
2026-06-01 |
2025-09-11 |
Primary Endpoints|Treatments |
|
NCT06693375 |
NEIS001 | P2 |
Recruiting |
Colorectal Cancer |
2026-05-01 |
2% |
2024-11-19 |
Primary Endpoints |
NCT06257537 |
KP-01-2024 | P2 |
Recruiting |
Osteoarthritis, Knee |
2026-02-01 |
50% |
2025-02-13 |
Primary Endpoints |
NCT04559685 |
NCT04559685 | P1 |
Recruiting |
Glioma |
2026-03-01 |
50% |
2025-03-18 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
NCT05883241 |
BF-01-2023 | P1 |
Recruiting |
Pain Unspecified |
2026-02-01 |
50% |
2025-03-01 |
Primary Endpoints |
NCT06510062 |
CR-01-2024 | P1 |
Completed |
Other |
2024-09-30 |
2025-03-07 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
|
NCT07343986 |
BATs FUS | P1 |
Recruiting |
Glioblastoma |
2027-12-01 |
2026-01-16 |
Primary Endpoints|Treatments |
|
NCT06024772 |
Clinical | P3 |
Not yet recruiting |
Prostate Cancer |
2026-08-01 |
2024-03-09 |
Primary Endpoints |
|
NCT07209527 |
TruDxPC | P1 |
Enrolling by invitation |
Hyperlipidemia|Obesity|Acute Kidney Injury|Peripheral Vascular Diseases|Hypertension, Renal|Peripheral Arterial Disease|Prediabetic State|Kidney Failure, Chronic|Prediabetes|Type 2 Diabetes|Overweight |
2028-10-01 |
50% |
2025-10-08 |
Primary Endpoints |
NCT03107520 |
NCT03107520 | P1 |
Recruiting |
Hip Dislocation, Congenital |
2027-04-01 |
2025-04-18 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT07033689 |
SUNRISE-II | P1 |
Not yet recruiting |
Pancreatic Cancer|Adenocarcinoma |
2026-12-01 |
50% |
2025-06-25 |
Primary Endpoints|Treatments |
NCT05254574 |
OA-01-2022 | P1 |
Recruiting |
Osteoarthritis |
2026-05-01 |
50% |
2025-02-28 |
Primary Completion Date|Primary Endpoints |
NCT03952637 |
19-HG-0101 | P2 |
Recruiting |
GM1 Gangliosidosis|Gangliosidoses|Gangliosidosis, GM1 |
2028-01-01 |
12% |
2025-08-27 |
Primary Endpoints |
ACTRN12625000243415 |
ACTRN12625000243415 | P3 |
Not yet recruiting |
Osteoarthritis, Knee |
2025-07-05 |
2026-02-15 |
Treatments |
|
NCT07385846 |
UCCC-BN-25-02 | P1 |
Not yet recruiting |
Glioblastoma |
2028-06-01 |
50% |
2026-02-05 |
|
NCT05723107 |
NCT05723107 | P1 |
Recruiting |
Pancreatic Cancer |
2027-11-01 |
2025-11-29 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT07240857 |
ACT#001 | P1 |
Not yet recruiting |
Prostate Cancer |
2026-10-31 |
2025-11-22 |
Primary Endpoints|Treatments |
|
NCT05362409 |
CV01-101 | P1 |
Completed |
Glioma |
2024-12-03 |
50% |
2025-06-21 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT07185165 |
ECLIPSE | P2 |
Recruiting |
Prostate Cancer |
2035-10-25 |
2025-11-11 |
Primary Endpoints |
|
ACTRN12616001259437 |
ACTRN12616001259437 | P2 |
Not yet recruiting |
Osteoarthritis, Knee |
2025-02-03 |
2026-02-15 |
Treatments |
|
NCT05882812 |
KP-01-2022 | P2 |
Completed |
Osteoarthritis, Knee |
2023-12-31 |
50% |
2024-02-29 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
ACTRN12621001657819p |
2006-7041-83/hah | P2 |
Not yet recruiting |
Arthritis, Rheumatoid |
None |